However, the evidence of a role for MYC in platinum resistant SCLC remains circumstantial, primarily derived from the observation that MYC amplification is more frequent in cell lines derived from platinum resistant patients than treatment naïve lines [10]. This evidence concerns the gene MYC and small cell lung carcinoma.